Known as histotripsy, the device not only kills cancer cells but also stimulates the immune system as an added defense.

Trial will evaluate the safety and efficacy of histotripsy against liver tumors at eight U.S. sites.

The liver siphons critical immune cells to render immunotherapy ineffective; radiation to the liver may block this process.

A hepatologist comments on the new USPSTF guidelines for detecting hepatitis B in non-pregnant adults and adolescents. 

An international team of researchers conducts a study that defines a simple, low-cost blood test that yields high-performing results in the elimination of hepatitis C.

A collaborative U-M team shows that liver injury is less likely to originate from popular cancer immunotherapy drug, pembrolizumab, than tumor progression.